XNCR

Xencor Inc

Add to Watchlist

Advanced Chart

9.240

0(0.000%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

9.360

Open

9.240

VWAP

9.21

Vol

454.80K

Mkt Cap

657.62M

Low

9.000

Amount

4.19M

EV/EBITDA(TTM)

Total Shares

61.66M

342.43M

EV/OCF(TTM)

P/S(TTM)

4.95

Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases. It has more than 20 candidates engineered with its XmAb technology that are in clinical development, and multiple XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly-owned development candidates include XmAb942, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Its clinical-stage drug candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, Xpro1595, Obexelimab, and Novartis XmAb, an undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of efbalropendekin alfa (XmAb306/RG6323). Its Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2025Q3

FY2025Q2

31.75M

-39.85%

24.37M

+127.55%

22.59M

+33.21%

Estimates Revision

The market is revising Upward the revenue expectations for Xencor, Inc. (XNCR) for FY2025, with the revenue forecasts being adjusted by 6.62% over the past three months. During the same period, the stock price has changed by -12.83%.

Revenue Estimates for FY2025

Revise Upward

+6.62%

In Past 3 Month

Stock Price

Go Down

-12.83%

In Past 3 Month

11 Analyst Rating

191.02% Upside

Wall Street analysts forecast XNCR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for XNCR is 26.89 USD with a low forecast of 6.00 USD and a high forecast of 38.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

10 Buy

0 Hold

1 Sell

Strong Buy

191.02% Upside

Current: 9.240

Low

6.00

Averages

26.89

High

38.00

191.02% Upside

Current: 9.240

Low

6.00

Averages

26.89

High

38.00

Barclays

Underweight

downgrade

$22 -> $6

2025-05-08

Reason

Barclays

Price Target

$22 -> $6

2025-05-08

downgrade

Underweight

Reason

William Blair

Matt Phipps

Buy

Initiates

n/a

2025-04-21

Reason

William Blair

Matt Phipps

Price Target

n/a

2025-04-21

Initiates

Buy

Reason

Wells Fargo

Eva Fortea Verdejo

Buy

Maintains

$37 → $33

2025-02-28

Reason

Wells Fargo

Eva Fortea Verdejo

Price Target

$37 → $33

2025-02-28

Maintains

Buy

Reason

Wells Fargo

Eva Fortea Verdejo

Buy

Initiates

$37

2024-12-12

Reason

Wells Fargo

Eva Fortea Verdejo

Price Target

$37

2024-12-12

Initiates

Buy

Reason

Wells Fargo analyst Eva Fortea Verdejo initiated coverage of Xencor with an Overweight rating and $37 price target. The firm doesn't think the Street is pricing in enough value for Xencor's pipeline opportunities, and key updates for both XmAb819 and XmAb942 should offer significant upside in the next 6-12 months. Further, Wells thinks the company's multiple partnerships highly de-risks its approach to antibody drug design.

Piper Sandler

Edward Tenthoff

Hold

Buy

Upgrades

$20 → $30

2024-12-02

Reason

Piper Sandler

Edward Tenthoff

Price Target

$20 → $30

2024-12-02

Upgrades

Hold

Buy

Reason

Piper Sandler upgraded Xencor to Overweight from Neutral with a price target of $30, up from $20. Xencor is expanding its XmAb technology into autoimmune disease and will report initial Phase I healthy volunteer data on XmAb942 in the first half of 2025, the analyst tells investors in a research note. The firm tells investors to own the shares into the 2025 data.

BMO Capital

Etzer Darout

Buy

Reiterates

$32 → $34

2024-11-08

Reason

BMO Capital

Etzer Darout

Price Target

$32 → $34

2024-11-08

Reiterates

Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Xencor Inc (XNCR.O) is -3.53, compared to its 5-year average forward P/E of -3.13. For a more detailed relative valuation and DCF analysis to assess Xencor Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-3.13

Current PE

-3.53

Overvalued PE

31.61

Undervalued PE

-37.88

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

11.02

Current EV/EBITDA

-0.77

Overvalued EV/EBITDA

80.48

Undervalued EV/EBITDA

-58.45

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Undervalued

5Y Average PS

16.01

Current PS

5.89

Overvalued PS

22.38

Undervalued PS

9.64